Cargando…

Overcoming EZH2 Inhibitor Resistance by Taxane in PTEN-Mutated Cancer

Rationale: The Polycomb group (PcG) protein EZH2 is implicated in cancer progression due to its frequent overexpression in many cancer types and therefore is a promising therapeutic target. Forkhead box transcription factor-1 (FOXO1) is a tumor suppressor that is often transcriptionally downregulate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Linlin, Yan, Yuqian, Bai, Yang, Yang, Yinhui, Pan, Yunqian, Gang, Xiaokun, Karnes, R. Jeffrey, Zhang, Jun, Lv, Qiubo, Wu, Qiang, Huang, Haojie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2019
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691386/ https://www.ncbi.nlm.nih.gov/pubmed/31410199 http://dx.doi.org/10.7150/thno.34700

Ejemplares similares

RUNX2 overexpression and PTEN haploinsufficiency cooperate to promote CXCR7 expression and cellular trafficking, AKT hyperactivation and prostate tumorigenesis
por: Bai, Yang, et al.
Publicado: (2019)

P300 acetyltransferase regulates fatty acid synthase expression, lipid metabolism and prostate cancer growth
por: Gang, Xiaokun, et al.
Publicado: (2016)

Dual inhibition of AKT‐mTOR and AR signaling by targeting HDAC3 in PTEN‐ or SPOP‐mutated prostate cancer
por: Yan, Yuqian, et al.
Publicado: (2018)

Inhibition of EZH2 by chemo- and radiotherapy agents and small molecule inhibitors induces cell death in castration-resistant prostate cancer
por: Wu, Changping, et al.
Publicado: (2015)

Platinum drugs and taxanes: can we overcome resistance?
por: Sazonova, Elena V., et al.
Publicado: (2021)

LncRNA MALAT1 enhances oncogenic activities of EZH2 in castration-resistant prostate cancer
por: Wang, Dejie, et al.
Publicado: (2015)

Targeting Ezh2 could overcome docetaxel resistance in prostate cancer cells
por: Qiu, Xiaofu, et al.
Publicado: (2019)

Overcoming TRAIL-resistance by sensitizing prostate cancer 3D spheroids with taxanes
por: Grayson, Korie A., et al.
Publicado: (2021)

NOTCH and EZH2 collaborate to repress PTEN expression in breast cancer
por: Pappas, Kyrie, et al.
Publicado: (2021)

Enhancing Saccharomyces cerevisiae Taxane Biosynthesis and Overcoming Nutritional Stress-Induced Pseudohyphal Growth
por: Walls, Laura Ellen, et al.
Publicado: (2022)

Pharmacological inhibition of noncanonical EED-EZH2 signaling overcomes chemoresistance in prostate cancer
por: Li, Xin, et al.
Publicado: (2021)

Salvianolic acid B attenuates tubulointerstitial fibrosis by inhibiting EZH2 to regulate the PTEN/Akt pathway
por: Lin, Pinglan, et al.
Publicado: (2022)

Adjuvant therapy of endometrial cancer: “taxane or not taxane, this is the question”
por: Lorusso, Vito, et al.
Publicado: (2019)

Mutations in BRCA2 and taxane resistance in prostate cancer
por: Nientiedt, Cathleen, et al.
Publicado: (2017)

SPOP mutation induces DNA methylation via stabilizing GLP/G9a
por: Zhang, Jianong, et al.
Publicado: (2021)

E2F7−EZH2 axis regulates PTEN/AKT/mTOR signalling and glioblastoma progression
por: Yang, Rui, et al.
Publicado: (2020)

Impact of taxanes on androgen receptor signaling
por: Bai, Shanshan, et al.
Publicado: (2019)

EZH2 takes the stage when BRCA1 loses
por: Wang, Lan, et al.
Publicado: (2013)

Combined PDGFR and HDAC Inhibition Overcomes PTEN Disruption in Chordoma
por: Lee, Dae-Hee, et al.
Publicado: (2015)

lncRNA HOTTIP Recruits EZH2 to Inhibit PTEN Expression and Participates in IM Resistance in Chronic Myeloid Leukemia
por: Liu, Jing, et al.
Publicado: (2022)

Small molecule inhibition of the CHFR-PARP1 interaction as novel approach to overcome intrinsic taxane resistance in cancer
por: Brodie, Seth A., et al.
Publicado: (2015)

Topoisomerase II alpha inhibition can overcome taxane-resistant prostate cancer through DNA repair pathways
por: Hongo, Hiroshi, et al.
Publicado: (2021)

Inhibiting histone deacetylases suppresses glucose metabolism and hepatocellular carcinoma growth by restoring FBP1 expression
por: Yang, Jing, et al.
Publicado: (2017)

Hedgehog Signaling Overcomes an EZH2-Dependent Epigenetic Barrier to Promote Cholangiocyte Expansion
por: Jalan-Sakrikar, Nidhi, et al.
Publicado: (2016)

P-gp and taxanes
por: Hendrikx, Jeroen J.M.A., et al.
Publicado: (2014)

Mechanisms of Taxane Resistance
por: Maloney, Sara M., et al.
Publicado: (2020)

HDAC1,2 inhibition impairs EZH2- and BBAP- mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma
por: Johnson, Danielle P., et al.
Publicado: (2014)

Taxane-induced acute interstitial pneumonitis in patients with breast cancer and outcome of taxane rechallenge
por: Anoop, T M, et al.
Publicado: (2022)

Neoadjuvant chemotherapy outcome with taxane-based versus non-taxane protocols in gastric cancer
por: Kianersi, Shirin, et al.
Publicado: (2023)

NFATc1 Promotes Prostate Tumorigenesis and Overcomes PTEN Loss-Induced Senescence
por: Manda, Kalyan R., et al.
Publicado: (2015)

Taxane-Induced Peripheral Neurotoxicity
por: Velasco, Roser, et al.
Publicado: (2015)

Sex Differences in Taxane Toxicities
por: Chmielewski, Nicole N., et al.
Publicado: (2022)

Discussion on the use of taxanes for treatment of breast cancers in BRCA1 mutations carriers
Publicado: (2007)

STAT3-Induced Upregulation of lncRNA CASC9 Promotes the Progression of Bladder Cancer by Interacting with EZH2 and Affecting the Expression of PTEN
por: Yuan, Bo, et al.
Publicado: (2020)

LncRNA GAS5 facilitates nasopharyngeal carcinoma progression through epigenetically silencing PTEN via EZH2
por: Zhao, Dan, et al.
Publicado: (2019)

Mutational mechanisms of EZH2 inactivation in myeloid neoplasms
por: Chase, Andrew, et al.
Publicado: (2020)

Overcoming the therapeutic limitations of EZH2 inhibitors in Burkitt’s lymphoma: a comprehensive study on the combined effects of MS1943 and Ibrutinib
por: Jeong, Yurim, et al.
Publicado: (2023)

Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors
por: Munster, Pamela N., et al.
Publicado: (2022)

Therapeutic inhibition of USP7-PTEN network in chronic lymphocytic leukemia: a strategy to overcome TP53 mutated/deleted clones
por: Carrà, Giovanna, et al.
Publicado: (2017)

Polymorphisms in AURKA and AURKB are associated with the survival of triple-negative breast cancer patients treated with taxane-based adjuvant chemotherapy
por: Liao, Yuqian, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_g0ju8jgvkvmtcdqu0p2gbcb3o7